FDA approves first new schizophrenia treatment, Cobenfy, by Bristol Myers Squibb in 70+ years.
The FDA has approved Cobenfy, a novel schizophrenia treatment from Bristol Myers Squibb, marking the first new drug type in over 70 years. The twice-daily pill, expected to launch in late October, costs $1,850 monthly or $22,500 annually before insurance. Cobenfy targets brain receptors to reduce symptoms without typical antipsychotic side effects, providing a much-needed option for the nearly 3 million affected adults in the U.S.
September 26, 2024
74 Articles